Construction underway of Zayed Centre featuring new ‘cleanrooms’ for the production of gene and cell therapy medicinal products

16 Sep 2016, 11:06 a.m.

The Zayed Centre for Research into Rare Disease in Children (ZCR) is currently under construction in Guildford Street. Importantly this will include a dedicated facility comprising seven ‘cleanrooms’ where gene and cell therapy medicinal products can be made to treat children compassionately or on a clinical trial.

Currently GOSH has two ‘cleanrooms’ which are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) as compliant with “Good Manufacturing Practice (GMP)” and one ‘cleanroom’ for routine bone marrow manipulations licensed by the Human Tissue Authority (HTA). However, these rooms are close to maximum capacity at present. As so many new advanced therapy products are being developed to treat an ever wider range of diseases, the new ZCR GMP will provide essential new capacity by 2018, when the facility opens. It is not easy to predict exactly what new treatments will become available, but so far these include: severe combined immunodeficiencies, different types of leukaemia, whole tumours, skin disorders and viral infection post bone marrow transplant.

Gene therapy offers potential to extend lives of children with rare immune disorder

Children have had their lives changed by a ground-breaking gene therapy treatment at Great Ormond Street Hospital for a rare immunodeficiency.

Join us in the countdown to Rare Disease Day 2025

Rare Disease Day takes place annually on the last day of February and is a global opportunity to increase awareness and advocate for those living with rare conditions.

Twelve days of Research and Innovation at GOSH

It’s been a busy year for Research and Innovation at GOSH, with a number of ground breaking research trials, advanced data projects and technology pilots. To round off the year, here are just twelve of the stories (and amazing staff and researchers) that

Duchenne Muscular Dystrophy gene therapy trial highlights complexity of disease

The first large-scale trial of gene therapy for the debilitating neuromuscular disease, Duchenne Muscular Dystrophy (DMD) has been carried out